Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aptevo Therapeutics (APVO) Accounts Payables (2016 - 2025)

Aptevo Therapeutics (APVO) has disclosed Accounts Payables for 11 consecutive years, with $2.2 million as the latest value for Q3 2025.

  • Quarterly Accounts Payables fell 37.17% to $2.2 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $2.2 million through Sep 2025, down 37.17% year-over-year, with the annual reading at $1.2 million for FY2024, 68.83% down from the prior year.
  • Accounts Payables hit $2.2 million in Q3 2025 for Aptevo Therapeutics, down from $2.9 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.4 million in Q1 2021 to a low of $1.2 million in Q4 2024.
  • Historically, Accounts Payables has averaged $3.7 million across 5 years, with a median of $3.7 million in 2024.
  • Biggest five-year swings in Accounts Payables: skyrocketed 49.07% in 2023 and later tumbled 68.83% in 2024.
  • Year by year, Accounts Payables stood at $3.5 million in 2021, then increased by 1.07% to $3.5 million in 2022, then grew by 13.86% to $4.0 million in 2023, then crashed by 68.83% to $1.2 million in 2024, then surged by 78.66% to $2.2 million in 2025.
  • Business Quant data shows Accounts Payables for APVO at $2.2 million in Q3 2025, $2.9 million in Q2 2025, and $3.8 million in Q1 2025.